Clinical
Quotient Clinical offers a range of services specific to early drug development. Specialising in Phase I/IIa studies, drug product optimisation and 14C enabled drug development services, we provide full clinical support for early drug development programmes.
Phase I/IIa - We have a strong heritage in First-In-Human (FIH) studies, specialising in the delivery of differentiated, value added phase I/IIa clinical trials.
Drug Product Optimisation - Our unique integrated formulation, manufacturing and clinical testing facilities enable us to develop, manufacture and test a range of formulations in man, generating valuable data early on in the programme.
14C Enabled Drug Development – our unrivalled expertise in 14C radiolabelled drug delivery adds value to early drug development.
Our Clinical Capabilities
With capabilities covering all areas of early drug development from Pharmaceutical Sciences, tailored regulatory support, on-site QPs through to biometrics and reporting, Quotient Clinical is the partner of choice for early clinical studies. Read more.
Our Unique Clinical Platforms
Quotient Clinical has developed a number of unique platforms to expedite your drug development programme. Learn more about how Translational Pharmaceutics™, Enterion™ drug absorption studies and scintigraphic imaging can add value to your drug candidates.
Contact us to find out more and to discuss your specific needs